©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2022; 28(25): 2881-2889
Published online Jul 7, 2022. doi: 10.3748/wjg.v28.i25.2881
Published online Jul 7, 2022. doi: 10.3748/wjg.v28.i25.2881
Incretin based therapy and pancreatic cancer: Realising the reality
Varun Suryadevara, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Dukhabandhu Naik, Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605006, India
Ayan Roy, Department of Endocrinology, All India Institute of Medical Sciences, Kalyani 741245, West Bengal, India
Pazhanivel Mohan, Department of Medical Gastroenterology, Jawaharlal Institute of Post
Raja Kalayarasan, Department of Surgical Gastroenterology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605006, India
Author contributions: Suryadevara V and Roy A did the literature search and wrote the first draft; Sahoo J, Kamalanathan S and Naik D supervised the writing, gave intellectual inputs, and critically revised the manuscript; Mohan P and Kalayarasan R gave intellectual inputs and critically revised the manuscript; all of them approved the final version of the manuscript to be published.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article
Corresponding author: Jayaprakash Sahoo, MBBS, MD, Additional Professor, Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Room 5444, 4th Floor, Super Speciality Block, Puducherry 605006, India. jppgi@yahoo.com
Received: January 17, 2022
Peer-review started: January 17, 2022
First decision: March 9, 2022
Revised: March 23, 2022
Accepted: May 22, 2022
Article in press: May 22, 2022
Published online: July 7, 2022
Processing time: 167 Days and 19.4 Hours
Peer-review started: January 17, 2022
First decision: March 9, 2022
Revised: March 23, 2022
Accepted: May 22, 2022
Article in press: May 22, 2022
Published online: July 7, 2022
Processing time: 167 Days and 19.4 Hours
Core Tip
Core Tip: Incretin-based therapies are increasingly being used to treat patients with type 2 diabetes mellitus. The early literature regarding pancreatic safety of incretin-based therapies was discordant. However, the follow-up data of various randomised trials have consistently shown that these medications are safe.